EMIG
Confronting the ‘danger’ of blocking progress on clinical trial transparency
August 19, 2015Research and Development EMIG, Ethical Medicines Industry Group, Richmond Pharmacology, clinical trial registration, clinical trial transparency, health research authority, hra, sense about science, transparency
The Ethical Medicines Industry Group and Sense About Science – a co-founder of the ALLTrials campaign – have written a …
HRA must continue ‘progress towards clinical trial transparency’
August 19, 2015Research and Development EMIG, Ethical Medicines Industry Group, Richmond Pharmacology, clinical trial registration, clinical trial transparency, health research authority, hra, sense about science, transparency
Campaigners and industry leaders have urged the Health Research Authority to ensure that its work to bring about full transparency …
Ruling in transparency case ‘due within days’
July 17, 2015Research and Development EMIG, EU Clinical Trial Regulation, Ethical Medicines Industry Group, Richmond Pharmacology, alltrials, clinical trials, health research authority, hra, sense about science, transparency
A judge is set to rule on a controversial legal challenge to the requirement for the pharma industry to register …
NICE rejects ‘benefit’ test
January 28, 2014Sales and Marketing Dillon, EMIG, NHS, NICE, benefits
NICE has refused to include a ‘wider societal benefit’ test into its deliberations about which drugs should be available on …
PPRS deal ‘dreadful’, says EMIG
November 26, 2013Sales and Marketing EMIG, NHS, NICE, PPRS, VBP
The Ethical Medicines Industry Group (EMIG) has slammed the new PPRS plan, calling it a ‘dreadful deal’ for its members. …
NICE to assess drug value
March 22, 2013Sales and Marketing EMIG, NHS, NICE, VBP
NICE will be responsible for assessing the full value of medicines – taking into account their benefit to patients and …
VBP negotiations ‘opened up’
February 19, 2013Sales and Marketing ABPI, Cancer, EMIG, NHS, VBP
Patient views will for the first time be heard in negotiations between the Department of Health and ABPI about Value-Based …
Cancer Drugs Fund must not be forerunner to value-based pricing – EMIG
January 19, 2011Sales and Marketing Cancer Drugs Fund, EMIG, Ethical Medicines Industry Group, NHS, value-based pricing
The association representing small to medium UK pharma companies says the forthcoming Cancer Drugs Fund is welcome – but must …
Generic substitution will not deliver significant NHS savings, says EMIG
March 31, 2010Sales and Marketing EMIG, NHS, generics
The Department of Health’s plans for automatic generic substitution will not result in significant savings for the NHS and should …
